Publications by authors named "Pablo Borrega"

Claim this Profile
A
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial.
Joan Carles, Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Pablo Borrega

Eur Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Nuria Romero-Laorden, David Lorente, Guillermo de Velasco, Rebeca Lozano, Bernardo Herrera, Pablo Borrega

Eur Urol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study.
Jesús García-Donas, Guillermo de Velasco, Rodrigo Madurga, Jesús Chamorro, Diana Rosero, Pablo Borrega

Clin Transl Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study.
Yolanda Escobar, Avinash Ramchandani, Mercedes Salgado, Alfredo Castillo-Trujillo, Eva Martínez de Castro, Pablo Borrega

Clin Transl Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.
Joan Carles, Teresa Alonso-Gordoa, Begoña Mellado, María J Méndez-Vidal, Sergio Vázquez, Pablo Borrega

Eur J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Elena Castro, Nuria Romero-Laorden, Angela Del Pozo, Rebeca Lozano, Ana Medina, Pablo Borrega

J Clin Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
Antoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, Piotr Jan Wysocki, Nuria Lainez, Pablo Borrega

Clin Genitourin Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.
Angelo Gámez-Pozo, Luis M Antón-Aparicio, Cristina Bayona, Pablo Borrega, María I Gallegos Sancho

Neoplasia· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital.
Javier Salvador, Cristina Grávalos, Joan Albanell, Agustin Barnadas, Pablo Borrega

Clin Transl Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice.
Juan A Virizuela, Yolanda Escobar, Javier Cassinello, Pablo Borrega,

Clin Transl Oncol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functions and workload of medical oncologists in Spain.
Cristina Grávalos, Javier Salvador, Joan Albanell, Agustín Barnadas, Pablo Borrega

Clin Transl Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Pablo Borrega, Amalia Velasco, Matilde Bolaños, María del Mar Perez, José Ramón Mel

Urol Oncol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Juan José Reina, Jorge Aparicio, Javier Salvador, José María Puerto Pica, Antonio Rueda, Pablo Borrega

Cancer Chemother Pharmacol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis